Xeris Biopharma Holdings, Inc. (XERS) Reports Record $71.5M Q2 Revenue
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a Chicago-based commercial-stage biopharmaceutical company focused on therapies for chronic endocrine and neurological diseases.
Xeris Biopharma Holdings Inc. (XERS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | D E Shaw D. E. Shaw | 3,835,407 | $17,911,351 | +26% | 0.01% |
| 2. | 10,500,000 | $17,732,075 | 0.32% | ||
| 3. | Millennium Management Israel Englander | 2,933,620 | $13,700,005 | +27% | 0.01% |
| 4. | Parkman Healthcare Partners Greg Martinez | 2,107,483 | $9,841,946 | +19% | 1.13% |
| 5. | Driehaus Capital Richard Driehaus | 2,071,075 | $9,671,920 | +47% | 0.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.38 | 25,000 | $109,475.00 | 1,708,585 | 2025-06-13 | Filing | |
| $2.25 | 4,515 | $10,147.01 | 25,200 | 2024-08-12 | Filing | |
| $2.37 | 4,285 | $10,134.03 | 20,685 | 2024-08-09 | Filing | |
| $1.91 | 5,400 | $10,314.00 | 16,400 | 2024-05-10 | Filing | |
| $2.16 | 4,500 | $9,720.00 | 11,000 | 2024-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $7.72 | 15,500 | $119,610.40 | 142,000 | 2025-09-11 | Filing | |
| $7.92 | 42,232 | $334,515.45 | 219,188 | 2025-08-28 | Filing | |
| $7.32 | 107,500 | $786,459.25 | 833,483 | 2025-08-13 | Filing | |
| $7.28 | 42,500 | $309,225.75 | 115,000 | 2025-08-12 | Filing | |
| $5.43 | 40,000 | $217,244.00 | 1,353,510 | 2025-03-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,536,321 | $53,874,619 | 0% | |
| 2. | 9,816,937 | $45,845,097 | 0% | |
| 3. | 23,074,000 | $39,197,396 | 0.1% | |
| 4. | 3,783,200 | $17,667,544 | 0% | |
| 5. | 3,650,688 | $17,052,409 | 0% |
News See All
10 Best Biotech Stocks to Buy Under $10
The head biotech analyst at Goldman Sachs, Salveen Richter, appeared on CNBC's "Squawk Box" on July 25 to discuss various topics, including the current status of the biotech industry and what to expect...
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2025 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q2 2025 Earnings Call Transcript August 7, 2025Xeris Biopharma Holdings, Inc. beats earnings expectations.
11 Unstoppable Growth Stocks to Invest in Now
BlackRock highlighted that the trade conflict between the US and China continues to cause major economic disruptions.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q1 2025 Earnings Call Transcript
Operator: Good morning. Thank you for attending today's Xeris Biopharma Holdings, Inc. First Quarter 2025 Results Conference Call. My name is Makaya, and I'll be the moderator for today's call.
10 Best Multibagger Penny Stocks to Buy According to Billionaires
Penny stocks always seem like bargains for gaining exposure to some of the fastest-growing segments or spectacles, especially when popular stocks cost hundreds or thousands of dollars.
10 Hot Biotech Stocks Under $5
The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing investor attention.
12 Best Stocks to Invest in for a Stock Market Game
We all have heard the phrase ‘value isn’t always visible at first glance’ at least once in our lifetime and this isn’t something to overlook, particularly when you are playing the stock game.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to the Xeris Biopharma Fourth Quarter and Full Year 2024 Financial Results. My name is Harry and I'll be your operator today.
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Call Transcript
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Q3 2024 Earnings Call Transcript November 8, 2024Xeris Biopharma Holdings, Inc. beats earnings expectations.